These findings come at a time when the World Health Organization announced in its annual report that tuberculosis remains a "major global health problem" and the leading infectious cause of death worldwide, with 10.7 million people infected and another 1.23 million dying from the disease in the past year alone.
In this context, researchers from the TB Alliance presented promising results on a new drug called sorfequiline at the Alliance's Lung Health Conference in Copenhagen. This new antibiotic demonstrated greater effectiveness against tuberculosis bacteria compared to current treatments, with a similar safety profile.
The clinical trial included 309 people from 22 research sites across South Africa, the Philippines, Georgia, Tanzania, and Uganda. Although all participants had a common type of tuberculosis treatable with conventional drugs, researchers believe this new drug may also be beneficial in treating more difficult-to-treat forms of tuberculosis that are resistant to standard medications.
Commenting on these results, Dr. Maria Beaumont, Vice President of the TB Alliance, explained that the survicoline-based treatment regimen can be used for anyone diagnosed with TB, without needing to wait for further tests to determine the type of TB and its drug sensitivity. She added, "I can start treatment immediately while I wait for a thorough understanding of the case, without all these complicated procedures."
This development comes at a time when access to rapid diagnostic tests for tuberculosis suffers from significant variations between different regions, where in some areas it may take days or even weeks to determine the type of tuberculosis before appropriate treatment can begin.
For his part, Dr. William Brumskine, clinical research site leader at the Aurum Institute in South Africa, expressed optimism about the impact of this development on the quality of healthcare, noting that "a shorter global treatment regimen with fewer side effects means fewer clinic visits, giving healthcare providers more time for individual patient care."
It is worth noting that a decade ago, patients with drug-resistant tuberculosis faced a grueling treatment regimen of 18 months or more, involving multiple injections and extended hospital stays, with a success rate of only 50%. In contrast, the current gold standard treatment, introduced in 2019, has revolutionized the field, curing 90% of patients in just six months, and researchers hope that survicoline will contribute to further improvements.
The Tuberculosis Alliance is scheduled to announce a Phase III clinical trial in 2026. In this regard, Dr. Kavindran Velen, Chief Scientific Officer of the International Union Against Tuberculosis and Lung Disease, noted that faster and more effective TB treatment could yield significant benefits, including increasing the percentage of patients who complete treatment and reducing the infectious period of the disease.
However, he also warned that the universal application of a single treatment to all tuberculosis patients could have some downsides, such as discouraging health systems from investing in broader innovations like laboratories and advanced testing.
it is noted that progress in the fight against tuberculosis is facing increasing threats due to global aid cuts, putting the achievement of the United Nations goals to eliminate TB as a public health threat this decade at risk.
